Skip to main content

Advertisement

SpringerLink
Log in

A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This phase I study investigated the safety, dose-limiting toxicity, and efficacy in three cohorts all treated with the mTOR inhibitor everolimus that was delivered (1) in combination with 5-fluorouracil with leucovorin (5-FU/LV), (2) with mFOLFOX6 (5-FU/LV + oxaliplatin), and (3) with mFOLFOX6 + panitumumab in patients with refractory solid tumors.

Methods

Patients were accrued using a 3-patient cohort design consisting of two sub-trials in which the maximum tolerated combination (MTC) and dose-limiting toxicity (DLT) of everolimus and 5-FU/LV was established in Sub-trial A and of everolimus in combination with mFOLFOX6 and mFOLFOX6 plus panitumumab in Sub-trial B.

Results

Thirty-six patients were evaluable for toxicity, 21 on Sub-trial A and 15 on Sub-trial B. In Sub-trial A, DLT was observed in 1/6 patients enrolled on dose level 1A and 2/3 patients in level 6A. In Sub-trial B, 2/3 patients experienced DLT on level 1B and subsequent patients were enrolled on level 1B-1 without DLT. Three of six patients in cohort 2B-1 experienced grade 3 mucositis, and further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted. Among the 24 patients enrolled with refractory metastatic colorectal cancer, the median time on treatment was 2.7 months with 45 % of patients remaining on treatment with stable disease for at least 3 months.

Conclusions

While a regimen of everolimus in addition to 5-FU/LV and mFOLFOX6 appears safe and tolerable, the further addition of panitumumab resulted in an unacceptable level of toxicity that cannot be recommended for further study. Further investigation is warranted to better elucidate the role which mTOR inhibitors play in patients with refractory solid tumors, with a specific focus on mCRC as a potential for the combination of this targeted and cytotoxic therapy in future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  2. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3 K pathway as drug target in human cancer. J Clin Oncol 28:1075–1083

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Houghton PJ (2010) Everolimus. Clin Cancer Res 16:1368–1372

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554

    Article  CAS  PubMed  Google Scholar 

  5. Bradshaw-Pierce EL, Pitts TM, Kulikowski G et al (2013) Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS ONE 8:e58089

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Chu C, Noel-Hudson MS, Boige V et al (2013) Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. Fundam Clin Pharmacol 27:434–442

    Article  CAS  PubMed  Google Scholar 

  7. Altomare I, Hurwitz H (2013) Everolimus in colorectal cancer. Expert Opin Pharmacother 14:505–513

    Article  CAS  PubMed  Google Scholar 

  8. Altomare I, Bendell JC, Bullock KE et al (2011) A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist 16:1131–1137

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Ng K, Tabernero J, Hwang J et al (2013) Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res 19:3987–3995

    Article  CAS  PubMed  Google Scholar 

  10. Wolpin BM, Ng K, Zhu AX et al (2013) Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18:377–378

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Wang Q, Wei F, Li C et al (2013) Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PLoS ONE 8:e73175

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Wang HW, Yang SH, Huang GD et al (2014) Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol 140:561–571

  13. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931–937

    Article  CAS  PubMed  Google Scholar 

  14. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  CAS  PubMed  Google Scholar 

  15. Soefje SA, Karnad A, Brenner AJ (2011) Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 6:125–129

    Article  PubMed  Google Scholar 

  16. Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, School of Medicine, The University of North Carolina at Chapel Hill, Physicians Office Building, 170 Manning Drive, Campus Box #7305, Chapel Hill, NC, 27599, USA

    Autumn J. McRee, Hanna G. Sanoff, Stephen Bernard, E. Claire Dees, Kimberly Keller & Anastasia Ivanova

  2. School of Medicine, BC Cancer Agency, Kelowna, BC, Canada

    Janine M. Davies

  3. School of Medicine, The Ohio State University, Columbus, OH, USA

    Richard M. Goldberg

  4. Department of Medicine, Indiana University, Indianapolis, IN, USA

    Bert H. O’Neil

Authors
  1. Autumn J. McRee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janine M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanna G. Sanoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard M. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Claire Dees
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kimberly Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anastasia Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bert H. O’Neil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Autumn J. McRee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McRee, A.J., Davies, J.M., Sanoff, H.G. et al. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemother Pharmacol 74, 117–123 (2014). https://doi.org/10.1007/s00280-014-2474-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2474-0

Keywords

Search

Navigation